Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Nivolumab

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 2 (1)

Trial Status

Completed1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT05701176Not ApplicableRecruitingPrimary

A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer

NCT02350764Phase 2CompletedPrimary

Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs

Showing all 2 trials

Research Network

Common Treatments

  • Nivolumab1
  • 18ffarag Pet Scan1
  • Pilimumab1

Active Sponsors

  • Bristol-Myers Squibb1
  • Memorial Sloan Kettering Cancer Center1
  • Amsterdam UMC, location VUmc1
  • Boehringer Ingelheim1

Top Investigators

Activity Timeline